TARA · Protara Therapeutics Inc

-

Please sign in to comment on TARA

1 Comment

Admin

4 years ago

Protara Therapeutics, Inc is currently in a long term downtrend where the price is trading 49.6% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Protara Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 97.9% to $-34K since the same quarter in the previous year.

Finally, its free cash flow fell by 6941.8% to $-222M since the same quarter in the previous year.

Based on the above factors, Protara Therapeutics, Inc gets an overall score of 2/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US74365U1079
Sector	Healthcare
Industry	Biotechnology

Target Price	25
Market Cap	151M
PE Ratio	None
Beta	1.59
Dividend Yield	None

ABOUT

Protara Therapeutics Inc

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

TARA · Protara Therapeutics Inc

-

Protara Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Protara Therapeutics Inc using a moving average strategy